Hendrik Schulze-Koops
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Smolen J, Landewé R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards C, Hyrich K, Pope J, de Souza S, Stamm T, Takeuchi T, Verschueren P, Winthrop K, Balsa A, Bathon J, Buch M, Burmester G, Buttgereit F, Cardiel M, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder A, El Aoufy K, Finckh A, Fonseca J, Gottenberg J, Haavardsholm E, Iagnocco A, Lauper K, Li Z, McInnes I, Mysler E, Nash P, Poór G, Ristic G, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van Mil A, van Duuren E, Vliet Vlieland T, Westhovens R, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 2022
10.11.2022EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
10.11.2022Ann Rheum Dis 2022
Smolen Josef S, Landewé Robert B M, Bergstra Sytske Anne, Kerschbaumer Andreas, Sepriano Alexandre, Aletaha Daniel, Caporali Roberto, Edwards Christopher John, Hyrich Kimme L, Pope Janet E, de Souza Savia, Stamm Tanja, Takeuchi Tsutomu, Verschueren Patrick, Winthrop Kevin, Balsa Alejandro, Bathon Joan M, Buch Maya H, Burmester Gerd R, Buttgereit Frank, Cardiel Mario Humberto, Chatzidionysiou Katerina, Codreanu Catalin, Cutolo Maurizio, den Broeder Alfons A, El Aoufy Khadija, Finckh Axel, Fonseca João Eurico, Gottenberg Jacques-Eric, Haavardsholm Espen A, Iagnocco Annamaria, Lauper Kim, Li Zhanguo, McInnes Iain B, Mysler Eduardo F, Nash Peter, Poór Gyula, Ristic Gorica G, Rivellese Felice, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Stoilov Nikolay, Strangfeld Anja, van der Helm-van Mil Annette, van Duuren Elsa, Vliet Vlieland Theodora P M, Westhovens René, van der Heijde Désirée
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes I, Sattar N, Stamm T, Takeuchi T, Trauner M, van der Heijde D, Voshaar M, Winthrop K, Ravelli A, Betteridge N, Burmester G, Bijlsma J, Bykerk V, Caporali R, Choy E, Codreanu C, Combe B, Crow M, de Wit M, Emery P, Fleischmann R, Gabay C, Hetland M, Hyrich K, Iagnocco A, Isaacs J, Kremer J, Mariette X, Merkel P, Mysler E, Nash P, Nurmohamed M, Pavelka K, Poór G, Rubbert-Roth A, Schulze-Koops H, Strangfeld A, Tanaka Y, Smolen J. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis 2022
11.08.2022Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.
11.08.2022Ann Rheum Dis 2022
Aletaha Daniel, Kerschbaumer Andreas, Kastrati Kastriot, Dejaco Christian, Dougados Maxime, McInnes Iain B, Sattar Naveed, Stamm Tanja, Takeuchi Tsutomu, Trauner Michael, van der Heijde Désirée, Voshaar Marieke, Winthrop Kevin, Ravelli Angelo, Betteridge Neil, Burmester Gerd-Rüdiger, Bijlsma Johannes Wj, Bykerk Vivian, Caporali Roberto, Choy Ernest H S, Codreanu Catalin, Combe Bernard, Crow Mary K, de Wit Maarten, Emery Paul, Fleischmann Roy, Gabay Cem, Hetland Merete Lund, Hyrich Kimme L, Iagnocco Annamaria, Isaacs John D, Kremer Joel M, Mariette Xavier, Merkel Peter A, Mysler Eduardo F, Nash Peter, Nurmohamed Michael T, Pavelka Karel, Poór Gyula, Rubbert-Roth Andrea, Schulze-Koops Hendrik, Strangfeld Anja, Tanaka Yoshiya, Smolen Josef S
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.
01.01.2022Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
01.01.2022Clin Rheumatol 2022; 41:1045-1055
Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
Thalmann R, von Kempis J, Zgraggen A, Schiff M, Sokka T, Dietrich T, Schulze-Koops H, Mueller R. Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes. Clin Exp Rheumatol 2021
05.05.2021Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
05.05.2021Clin Exp Rheumatol 2021
Thalmann Reto, von Kempis Johannes, Zgraggen Armin, Schiff Michael, Sokka Tuulliki, Dietrich Tobias, Schulze-Koops Hendrik, Mueller Ruediger B
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
Kedor C, Specker C, Seipelt E, Schulze-Koops H, Rubbert-Roth A, Kekow J, Henes J, Blank N, Behrens F, Weiß A, Zernicke J, Listing J, Feist E. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020; 79:1090-1097.
13.05.2020Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
13.05.2020Ann Rheum Dis 2020; 79:1090-1097
Kedor Claudia, Specker Christof, Seipelt Eva, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Kekow Joern, Henes Joerg Christoph, Blank Norbert, Behrens Frank, Weiß Anja, Zernicke Jan, Listing Joachim, Feist Eugen
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med 2019; 8
26.09.2019Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
26.09.2019J Clin Med 2019; 8
Mueller Ruediger B, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Hasler Paul, Souza Alexander, Durmisi Mirsada, Mattow Frederik, Popp Florian, Hasler Caroline, von Kempis Johannes
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
Dörner T, Peters M, Schwenke H, Rubbert-Roth A, Krüger K, Kurthen R, Kellner H, Kästner P, Engel A, Schmalzing M, Iking-Konert C, Burmester G, Schulze-Koops H, Tony H. Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin Exp Rheumatol 2019; 37:937-945.
16.04.2019Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)
16.04.2019Clin Exp Rheumatol 2019; 37:937-945
Dörner Thomas, Peters Marvin A, Schwenke Holger, Rubbert-Roth Andrea, Krüger Klaus, Kurthen Reiner, Kellner Herbert, Kästner Peter, Engel Andreas, Schmalzing Marc, Iking-Konert Christof, Burmester Gerd-Rüdiger, Schulze-Koops Hendrik, Tony Hans-Peter
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Mueller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J Clin Med 2019; 8
03.03.2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
03.03.2019J Clin Med 2019; 8
Mueller Ruediger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
Müller R, Spaeth M, von Restorff C, Ackermann C, Schulze-Koops H, von Kempis J. Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. Journal of Clinical Medicine 2019; 8:302.
03.03.2019Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
03.03.2019Journal of Clinical Medicine 2019; 8:302
Müller Rüdiger B, Spaeth Michael, von Restorff Cord, Ackermann Christoph, Schulze-Koops Hendrik, von Kempis Johannes
The Value of an Automated Ultrasound System in the Detection of Synovitis
Mueller R, Grunke M, Wendler J, Schuch F, Hofmann-Preiss K, Boettger I, Jakobs R, Schulze-Koops H, von Kempis J. The Value of an Automated Ultrasound System in the Detection of Synovitis. Ultrasound Int Open 2018; 4:E61-E68.
11.07.2018The Value of an Automated Ultrasound System in the Detection of Synovitis
11.07.2018Ultrasound Int Open 2018; 4:E61-E68
Mueller Ruediger, Grunke Mathias, Wendler Jörg, Schuch Florian, Hofmann-Preiss Karina, Boettger Ina, Jakobs Rüdiger, Schulze-Koops Hendrik, von Kempis Johannes
Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
Mueller R, Kaegi T, Haile S, Schulze-Koops H, Schiff M, von Kempis J. Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort. RMD Open 2018; 4:e000673.
06.06.2018Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort
06.06.2018RMD Open 2018; 4:e000673
Mueller Ruediger B, Kaegi Toni, Haile Sarah R, Schulze-Koops Hendrik, Schiff Michael, von Kempis Johannes
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med 2018; 7
13.03.2018Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
13.03.2018J Clin Med 2018; 7
Heinimann Katja, von Kempis Johannes, Sauter Rafael, Schiff Michael, Sokka-Isler Tuulikki, Schulze-Koops Hendrik, Müller Rüdiger
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
Müller R, von Kempis J, Spaeth M, Schiff M, Schulze-Koops H, Haile S, Finckh A, Kaegi T, Reshiti N. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol 2016; 36:59-66.
12.11.2016Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
12.11.2016Clin Rheumatol 2016; 36:59-66
Müller Rüdiger, von Kempis Johannes, Spaeth Michael, Schiff Michael, Schulze-Koops Hendrik, Haile Sarah R, Finckh Axel, Kaegi Toni, Reshiti Nazim
Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort
Müller R, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, on behalf of the SCQM physicians. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford) 2013
17.12.2013Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort
17.12.2013Rheumatology (Oxford) 2013
Müller Rüdiger, Kaegi Toni, Finckh Axel, Haile Sarah, Schulze-Koops Hendrik, von Kempis Johannes, on behalf of the SCQM physicians
Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination
Müller R, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, Schulze-Koops H, von Kempis J. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol 2013; 31:723-30.
14.06.2013Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination
14.06.2013Clin Exp Rheumatol 2013; 31:723-30
Müller Rüdiger, Maier Reinhard, Hoschler Katja, Zambon Maria, Ludewig Burkhard, Herrmann Martin, Schulze-Koops Hendrik, von Kempis Johannes
Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor
Müller R, Skapenko A, Grunke M, Wendler J, Stuhlmuller B, Kalden J, Schulze-Koops H. Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis and rheumatism 2005; 52:451-60.
01.02.2005Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor
01.02.2005Arthritis and rheumatism 2005; 52:451-60
Müller Rüdiger, Skapenko Alla, Grunke Mathias, Wendler Jörg, Stuhlmuller Bruno, Kalden Joachim R, Schulze-Koops Hendrik